Gilead Sciences, Inc. vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $39.72. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | QDTY | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $46.71 |
52-Week Low | $110.56 | $36.57 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →